Study of new drug combinations for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer confirmed by biopsy or other tests.
- You are between 18 and 75 years old.
- You are able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your liver function is good (Child-Pugh A or no cirrhosis).
- You agree to provide a sample of your tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a new combination of drugs (envafolimab, suvemcitug, and HAIC) to shrink advanced or unresectable liver cancer. It is for people who have not had systemic treatment before and have good organ function.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.